Hear 55+ Presentations from Top Pharma at Drug Discovery Chemistry in San Diego
Cambridge Healthtech Institute's 14th Annual Drug Discovery Chemistry is a dynamic conference for medicinal and biophysical chemists working in pharma and biotech. As in the past, speaker participation by industry is once again very strong,
with presentations from, and discussions/trainings led by, AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, EMD Serono,
F. Hoffmann-La Roche, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, and Takeda. Preview the more than 55 presentations* below:
AbbVie
Considerations in the Generation of Covalent BTK Inhibitors
Noel S. Wilson, MSc, Senior Scientist III, Discovery Chemistry and Technology
Ligand-Receptor Molecular Interactions and Drug Design
Maricel Torrent, PhD, Principal Scientist, Molecular Modeling
Amgen
AMG176, a Selective MCL-1 Targeted Drug Candidate
Paul E. Hughes, PhD, Principal Scientist, Oncology Research
Modeling and Simulation to Study the Impact of Transporters on Drug Disposition and to Improve in vitro to in vivo Extrapolation (IVIVE)
Priyanka Kulkarni, PhD, Scientist, Pharmacokinetics and Drug Metabolism
Success and Challenges in Predicting Transporter Mediated Drug Disposition and Clearance from in vitro to in vivo Extrapolation
Na Li, PhD, Senior Scientist, Pharmacokinetics and Drug Metabolism
AstraZeneca
Discovery of AZD5991, a Potent and Selective Macrocyclic Mcl-1 Inhibitor for Treatment of Cancer
Scott Mlynarski, PhD, Senior Scientist, Oncology Chemistry, IMED Biotech Unit
The Discovery of Novel Allosteric MEK1 Binders by Fragment-Based Approaches
Paolo Di Fruscia, PhD, Senior Scientist, Structure Biophysics & FBLD, Discovery Sciences, IMED Biotech Unit
DEL for Membrane Proteins: Case Study of a GPCR
Dean G. Brown, PhD, Director, External Chemistry, Hit Discovery, Discovery Sciences, IMED Biotech Unit
Biogen
Artificial Intelligence in Kinase Inhibitor Discovery
Istvan J. Enyedy, PhD, Principal Scientist
Structural and Functional Characterization of Phospholipases as a Target for ALS
Jay Chodaparambil, PhD, Research Scientist, Chemical and Molecular Therapeutics
Design of an Artificial Intelligence System for Drug Discovery
Istvan Enyedy, PhD, Principal Scientist
Boehringer Ingelheim
Empirical & Structure-Based PROTAC Design: Lessons Learned with VHL-Based PROTACs
Peter Ettmayer, PhD, Scientific Director, Cancer Research
Bristol-Myers Squibb
The Good, the Bad, and the Confusing: Binding Kinetics at GPCR Targets and Potential Effects on Lead Optimization and Translatability
Brian Murphy, PhD, Senior Principal Scientist, CV and Fibrosis Drug Discovery, Disease Sciences and Biologics, R&D
Celgene
Cereblon Neosubstrate Degradation in Efficacy and Teratogenecity
Philip Chamberlain, DPhil, Senior Director, Structural and Chemical Biology
Solving a 60-Year Mystery: SALL4 Mediates Teratogenicity as a Thalidomide-Dependent Substrate of Cereblon
Mary Matyskiela, PhD, Principal Scientist, Structural and Chemical Biology
ADME Strategies in Beyond the Rule of Five Space
Ganesh Rajaraman, PhD, MBA, Associate Director, DMPK
Eli Lilly
Targeting the Tumor Microenvironment with TGFβ Inhibitors
Rikke B. Holmgaard, PhD, Principal Research Scientist, Oncology Research
BACE Inhibitor Drug Discovery - From Fragment-Based Hits to Clinical Candidates
Erik J. Hembre, PhD, Research Fellow, Discovery Chemistry Research
Discovery of Novel and Potent Spirocyclic RORγt Inhibitors
Chip Lugar, Senior Research Scientist, Discovery Chemistry Research
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor
Dustin Mergott, Senior Research Advisor, Group Leader, Discovery Chemistry Research & Technologies
Immunology Basics for Chemists
Songqing Na, PhD, Senior Scientist, Biotechnology & Autoimmunity Res-AME
Targeting Innate Immunity
Daniel Dairaghi, PhD, Senior Research Advisor, Medicinal Chemistry
Phage Display
Sepideh Afshar, PhD, Principal Research Scientist, Department of Protein Engineering
EMD Serono
A Kinase Platform for the Discovery of Reversible and Covalent Kinase Inhibitors
Igor Mochalkin, PhD, Associate Director
F. Hoffmann-La Roche
Targeting RNA: Discovery of Risdiplam; a Selective SMN2 Gene Splicing Modulator for the Treatment of Spinal Muscular Atrophy
Hasane Ratni, PhD, Expert Scientist, Medicinal Chemistry
Genentech, Inc.
Targeting the CBP/P300 Bromodomain for Immuno-Oncology
Karen Gascoigne, PhD, Scientist, Discovery Oncology
Antibody-Mediated Delivery of Protein Degraders
Peter Dragovich, PhD, Staff Scientist, Discovery Chemistry
Targeting Ubiquitin Ligases in Inflammatory Diseases
Domagoj Vucic, PhD, Principal Scientist, Early Discovery Biochemistry
Discovery of a Cross-Species Potent and Selective Inhibitor of Receptor-Interacting Protein Kinase (RIPK1) Providing Protection in a Number of Immunological Models
Snahel Patel, PhD, Scientist, Discovery Chemistry
Biotransformation of Antibody Drug Conjugates (ADCs) - Pathways and Enzymes
Donglu Zhang, PhD, Principal Scientist, Department of Drug Metabolism and Pharmacokinetics
Determining the Clinical Relevance of DDI Predictions
Kari Morrissey, PhD, Scientist, Clinical Pharmacology
Advanced Biophysical Methods for Driving Lead Generation in the Right Direction
Mela Mulvihill, PhD, Scientist, Biochemical & Cellular Pharmacology
Methodologies for Optimizing Drug Clearance and Drug-Drug Interactions
Zhengyin Yan, PhD, Principal Scientist, Department of Drug Metabolism and Pharmacokinetics
Donglu Zhang, PhD, Principal Scientist, Department of Drug Metabolism and Pharmacokinetics
Emerging Targets for Cancer Immunotherapy
Aditya Murthy, PhD, Scientist, Cancer Immunology
Gilead Sciences, Inc.
Discovery of GS-9876: A Selective SYK Inhibitor for the Treatment of Autoimmune Inflammatory Disorder
Peter Blomgren, PhD, Research Scientist II, Medicinal Chemistry
Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle
Petr Jansa, PhD, Senior Research Scientist II, Medicinal Chemistry
GlaxoSmithKline
Proteolysis Targeting Chimeric Molecules (PROTACs) as Small Molecule Modality in Immuno-Oncology
Markus Queisser, PhD, Scientific Leader, Protein Degradation DPU, R&D Future Pipelines Discovery
Discovery and Optimization of Potent and Selective TYK2 Pseudokinase Inhibitors through DNA-Encoded Library Technology
Ghotas Evindar, PhD, Head, Drug Design and Selection, Medicinal Science & Technology
Case Study: Optimization of a DEL Drug Candidate, RIP1K
Heather O'Keefe, PhD, Investigator, Medicinal Science and Technology
Small Molecule-Induced Protein Degradation with Proteolysis Targeting Chimeric Molecules (PROTACs)
Markus Queisser, PhD, Scientific Leader, Protein Degradation DPU, R&D Future Pipelines Discovery
Diversity-Oriented Platforms for Ligand Discovery: Focusing on DNA-Encoded Libraries
Svetlana Belyanskaya, PhD, Encoded Library Technologies, R&D Platform Technology & Science
Ghotas Evindar, PhD, Head, Post-Selection Chemistry Group, Encoded Library Technologies, R&D Platform Technology & Science
Janssen
Gene Signature Screen (GSS) to Identify Novel Modulators of a Transcriptional Factor
Seong Joo Koo, PhD, Senior Scientist, Lead Discovery
A New Era in Discovery of Solute Carrier (SLC) Transporter Modulators
Alan D. Wickenden, PhD, Scientific Director, Discovery Science
Methods to Identify PPI Modulators
Samantha J. Allen, PhD, Principal Scientist, Screening
Merck
Application of Fragment-Based Drug Discovery in the Identification of Novel FXIa Inhibitors for Thrombosis Prevention
Santhosh F. Neelamkavil, PhD, Director, Discovery Chemistry
An Alternate Inhibition Mechanism for the Deubiquitinase USP7 and its Consequences for Ubiquitin Chain Linkage Selectivity
Till Maurer, PhD, Director, NMR-Lead, Analytical Enabling Technologies
Third Wave of Macrocyclic Peptide Therapeutics: Benchmarking and Druggable Target Space
Tomi K. Sawyer, PhD, Distinguished Scientist, Peptide Drug Discovery & Innovative Technologies
Characterization of Novel STING Ligands Using SPR and Orthogonal Approaches
Gottfried Schroeder, PhD, Senior Scientist, Department of Pharmacology
Integrating Fragment, HTS and DEL Hit-finding Approaches
Robert D. Mazzola, PhD, Director, Chemical Research
Novartis
Fragment-Based Drug Discovery Campaigns with Protein Complexes that Mediate Protein-Protein Interactions
Charles Wartchow, PhD, Senior Investigator
Discovery of ABL001, an Allosteric Inhibitor of Bcr-Abl Kinase
Wolfgang Jahnke, PhD, Director and Leading Scientist, Chemical Biology and Therapeutics
Pfizer
Targeted Degradation of Bruton's Tyrosine Kinase (BTK)
Matthew Calabrese, PhD, Senior Principal Scientist and Structural Biology Lab Head, Structural and Molecular Sciences
Binding Kinetics and Thermodynamics to Understand and Enhance Selectivity of Kinase Inhibitors
Prakash Palde, PhD, Principal Scientist, Oncology Research Unit
Employing Photoredox Catalysis for the Synthesis of DNA- Encoded Libraries
Dominik Koelmel, PhD, Senior Scientist, DNA-Encoded Libraries
Characterization of Specific Naa50 Inhibitors Identified using a DNA Encoded Library: a Lead-Finding Case Study for a Challenging Target
Pei-Pei Kung, PhD, Associate Research Fellow, Medicinal Chemistry
Discovery to Approval: Medicinal Chemistry Retrospective of Lorlatinib, A Macrocyclic ALK Inhibitor for Metastatic and Resistance Non-Small Cell Lung Cancer
Ted. W. Johnson, PhD, Research Fellow, Design Chemistry
Quantitative Prediction of Complex Drug-Drug Interactions Involving CYP3A and P-glycoprotein: A Case Study of Anticancer Drug Bosutinib
Shinji Yamazaki, PhD, Department of Pharmacokinetics, Dynamics and Metabolism, La Jolla Laboratories
Engaging Kinases in Living Cells: Probing Drug-Target Interactions with Chemical Biology and Biophysical Tools
Jordan Carelli, PhD, Senior Scientist, Oncology RU
CryoEM Applied to Drug Discovery
Seungil Han, PhD, Associate Research Fellow, Structure Biology & Biophysics
Takeda
A Chemical Toxicologist's Perspective on the Validation and Application of Cutting-Edge in vitro Toxicity Assays for Lead Optimization
Tomoya Yukawa, PhD, Associate Scientific Fellow, Discovery Toxicology, Drug Safety Research & Evaluation
* As of 2/13/19 – Please see individual agenda pages for most up-to-date list of speakers